Literature DB >> 19083236

Increased risk of zoonotic Salmonella and Campylobacter gastroenteritis in patients with haematological malignancies: a population-based study.

Kim O Gradel1, Mette Nørgaard, Claus Dethlefsen, Henrik C Schønheyder, Brian Kristensen, Tove Ejlertsen, Henrik Nielsen.   

Abstract

We hypothesised that haematological malignancies increase the risk of acquiring zoonotic Salmonella or Campylobacter gastroenteritis. The population-based study comprised all first-time Salmonella/Campylobacter gastroenteritis cases in two Danish counties (1991-2003), with age- and gender-matched controls from the background population. We linked the study cohort to registries to obtain data on malignancies, chemotherapy (yes/no), and main comorbidities diagnosed before Salmonella/Campylobacter gastroenteritis. Based on this design, we determined incidence rate ratios (IRR) in conditional logistic regression analyses, and we used weighted mean regression curves to evaluate fluctuations in risk 0-5 years after the malignancy diagnosis. Sixty-eight of 13,324 cases (0.5%) and 29 of 26,648 controls (0.1%) had haematological malignancy before their Salmonella/Campylobacter gastroenteritis. Comorbidity-adjusted IRR for Salmonella/Campylobacter gastroenteritis in patients with haematological malignancy as compared to patients without malignancy were 4.46 [95% confidence intervals (CI), 2.88-6.90] for all individuals, 8.33 (95% CI, 4.31-16.1) for Salmonella, and 2.17 (95% CI, 1.15-4.08) for Campylobacter. Stratification on chemotherapy treatment did not change these estimates. In time-related analyses, IRR were 7-8 in the first 2 years after the haematological malignancy diagnosis and 4-5 in the following 3 years. Patients with haematological malignancy had increased long-term risk of enquiring Salmonella or Campylobacter gastroenteritis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19083236     DOI: 10.1007/s00277-008-0662-x

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  5 in total

Review 1.  Reducing the risk of pet-associated zoonotic infections.

Authors:  Jason W Stull; Jason Brophy; J S Weese
Journal:  CMAJ       Date:  2015-04-20       Impact factor: 8.262

Review 2.  The occurrence and prevention of foodborne disease in vulnerable people.

Authors:  Barbara M Lund; Sarah J O'Brien
Journal:  Foodborne Pathog Dis       Date:  2011-05-11       Impact factor: 3.171

3.  Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Crystal S Denlinger; Tara Sanft; K Scott Baker; Gregory Broderick; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Melissa Hudson; Nazanin Khakpour; Allison King; Divya Koura; Robin M Lally; Terry S Langbaum; Allison L McDonough; Michelle Melisko; Jose G Montoya; Kathi Mooney; Javid J Moslehi; Tracey O'Connor; Linda Overholser; Electra D Paskett; Jeffrey Peppercorn; William Pirl; M Alma Rodriguez; Kathryn J Ruddy; Paula Silverman; Sophia Smith; Karen L Syrjala; Amye Tevaarwerk; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Nicole R McMillian; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2018-10       Impact factor: 11.908

4.  Survivorship: immunizations and prevention of infections, version 2.2014.

Authors:  Crystal S Denlinger; Jennifer A Ligibel; Madhuri Are; K Scott Baker; Wendy Demark-Wahnefried; Don Dizon; Debra L Friedman; Mindy Goldman; Lee Jones; Allison King; Grace H Ku; Elizabeth Kvale; Terry S Langbaum; Kristin Leonardi-Warren; Mary S McCabe; Michelle Melisko; Jose G Montoya; Kathi Mooney; Mary Ann Morgan; Javid J Moslehi; Tracey O'Connor; Linda Overholser; Electra D Paskett; Jeffrey Peppercorn; Muhammad Raza; M Alma Rodriguez; Karen L Syrjala; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Nicole R McMillian; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2014-08       Impact factor: 11.908

5.  Do patients with recurrent episodes of campylobacteriosis differ from those with a single disease event?

Authors:  Julie Arsenault; André Ravel; Pascal Michel; Olaf Berke; Pierre Gosselin
Journal:  BMC Public Health       Date:  2011-01-12       Impact factor: 3.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.